Novartis Tasigna® trial shows superior results to Glivec®
In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1].
Original Source of Novartis Tasigna® trial shows superior results to Glivec®
